The Interaction of Acute-Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial
Open Access
- 1 December 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 37 (1) , 21-28
Abstract
Zoledronic acid (ZOL) as a yearly infusion is effective in reducing fracture risk. An acute-phase reaction (APR), consisting of flu-like symptoms within 3 days after infusion, is commonly seen. The objective of this analysis was to investigate whether APR occurrence influences drug efficacy. This analysis uses data from the 3-year randomized clinical trial, Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly-Pivotal Fracture Trial (HORIZON-PFT). APRs were identified as adverse events within 3 days of first infusion with higher frequency in ZOL than placebo. To compare mean 3-year change in bone mineral density (BMD) in ZOL versus placebo, among women with and without APR, t tests were used. Logistic regression was used to examine the relationship between APR occurrence and odds of incident morphometric vertebral fracture. Cox regression was used to determine the risk of nonvertebral and hip fractures for women with versus without APR. Logistic and Cox models were used to determine the risk of incident fracture in ZOL versus placebo for women with and without an APR. The analysis included 3862 women in the ZOL group and 3852 in placebo, with 42.4% in ZOL versus 11.8% in placebo experiencing an APR. The difference in BMD mean change for ZOL versus placebo was similar for women with and without an APR (all p interaction >0.10). Among ZOL women, those with APR had 51% lower vertebral fracture risk than those without (odds ratio [OR] = 0.49, p < 0.001). A similar but nonsignificant trend was observed for nonvertebral and hip fracture (relative hazard [RH] = 0.82, p = 0.10; RH = 0.70, p = 0.22, respectively). There was a greater treatment-related reduction in vertebral fracture risk among women with APR (OR = 0.19) than those without (OR = 0.38) (p interaction = 0.01). Our results suggest that women starting ZOL who experience an APR will have a larger reduction in vertebral fracture risk with ZOL. © 2021 American Society for Bone and Mineral Research (ASBMR).Keywords
Funding Information
- Asahi Kasei Therapeutics Corporation
- Funding for original HORIZON trial: Novartis: Pharma
- Asahi Kasei Therapeutics Corporation
- Novartis Pharma
This publication has 26 references indexed in Scilit:
- Inflammatory markers and the risk of hip fracture: The women's health initiativeJournal of Bone and Mineral Research, 2012
- Improving adherence in osteoporosis: a new management algorithm for the patient with osteoporosisExpert Opinion on Pharmacotherapy, 2011
- Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPPBritish Journal of Haematology, 2008
- Zoledronic Acid and Clinical Fractures and Mortality after Hip FractureNew England Journal of Medicine, 2007
- Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate: Review of Statistical AnalysisJournal of Bone and Mineral Research, 2007
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 2007
- Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral DensityNew England Journal of Medicine, 2002
- Defining Incident Vertebral Deformity: A Prospective Comparison of Several ApproachesJournal of Bone and Mineral Research, 1999
- Comparison of methods for defining prevalent vertebral deformities: The study of osteoporotic fracturesJournal of Bone and Mineral Research, 1995
- Vertebral fracture assessment using a semiquantitative techniqueJournal of Bone and Mineral Research, 1993